http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021120406-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c166a11d0618d4c5b3581126c6f829e4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
filingDate 2021-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f0e5845707e895125a6634687095f4a
publicationDate 2021-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2021120406-A
titleOfInvention Combination Therapeutic Compositions and Methods for Treating Cancer
abstract PROBLEM TO BE SOLVED: To provide a combination and a method of a therapeutic agent for treating cancer by using a combination therapy. It can activate (i) effective amounts of targeted therapeutics and (ii) human plasmacytoid dendritic cells, myeloid dendritic cells, or NK cells, or a combination thereof. A combination comprising an effective amount of an immunotherapeutic agent. [Selection diagram] FIG. 1A
priorityDate 2014-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467077024

Total number of triples: 33.